Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone Depot vs Olanzapine in Schizophrenia
NCT00236457Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Nov 2000
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of risperidone in schizophrenia, schizoaffective disorder, sponsored by Johnson & Johnson. Started Nov 2000; status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00236457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236457.